News

Dupixent sales spur Sanofi growth

Dupixent sales spur Sanofi growth, but profits fall short
Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported lower-than-expected profits after outlaying money to develop new treatments. Dupixent generated sales of €3.
Sanofi revises annual sales growth expectations on strong Dupixent demand
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments.
Sanofi’s Earnings Call Highlights Strong Growth and Optimism
Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade highlights Sanofi’s dedication to sustainable business practices.
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.
Sanofi sees 'manageable' impact from US tariffs, expects strong sales growth
Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth expectations for the year, banking on expanded demand for its anti-inflammatory drug Dupixent to treat more conditions.
Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth
The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and continued demand for its blockbuster medicine Dupixent.
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...
Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount
Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...
Sanofi outlines high single-digit sales growth for 2025 while advancing innovation pipeline and strategic acquisitions
Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.
Fierce Pharma3d
Sanofi touts tariff resilience for rest of 2025 as CEO admits many unknowns persist
Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...
Sanofi falls after Q2 profit misses despite sales beat on higher costs
Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...